From the ISHLT meeting in Montreal, Bill Cornwell shares highlights of the plenary address from Jack G. Copeland, M.D., this year’s recipient of the Pioneer in Transplantation award.
The use of perioperative beta-blockade for noncardiac surgery has been declining as a result of the controversial POISE study, which turned up evidence for harm associated with extended-release metoprolol in this setting. Now a large new observational study published in JAMA offers a contrary perspective by suggesting that perioperative beta-blockade may be beneficial in low-…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
The FDA’s Circulatory System Devices advisory panel gave a tepid endorsement to Abbott Laboratories’ MitraClip device on Wednesday. The panel met to evaluate use of the novel device in patients with significant symptomatic mitral regurgitation (MR) who have been determined by a cardiac surgeon to be too high risk for open mitral valve surgery and in whom existing…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Two controversial trials testing PFO closure in patients with cryptogenic stroke missed their primary endpoints but contained suggestions of possible benefit.
Despite the absence of any evidence demonstrating benefit or showing how best to use them, vena cava filters (VCF) are used in most hospitals. Now a new study published in JAMA Internal Medicine suggests that this same lack of evidence results in an extremely broad rate of use in different hospitals. An accompanying viewpoint raises the…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. Two large trials presented at the American College of Cardiology meeting in San Francisco and published simultaneously in…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Walking the walk on TAVR
The 5 year results of the SYNTAX (SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery) trial are now published. SYNTAX assessed the optimal revascularization strategy for patients with left main and/or 3-vessel disease by randomly assigning such patients to CABG or PCI (with a first-generation paclitaxel-eluting stent) and then determining the rate of…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
As transcatheter aortic valve implantation (TAVI) gains increasing acceptance, cardiologists and surgeons are exploring additional patient populations who may benefit from the procedure. A new paper in the Journal of the American College of Cardiology provides the first look at the use of TAVI in the small but important group of patients with pure, severe native aortic…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
In a startling break with tradition, the American College of Cardiology (ACC) and the Society of Thoracic Surgeons (STS) will manage and run their own clinical trials testing expanded uses for transcatheter aortic valve replacement (TAVR). The two medical groups have recently been granted an investigational device exemption (IDE) by the FDA for one such…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
